GleamWall
中文EN

IBAC IB Acquisition Corp.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1998781 · Fiscal year ends 09/30

Financial factors as of 2026-03-31 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-74.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA1.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity—
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.54x
Accruals ratio3.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue——
SG&A expense$748,908$523,974
Operating income-$748,908-$523,974
Interest expense—-$3.03M
Pretax income$4.38M$2.50M
Income tax$965,635$635,512
Net income$3.42M$1.87M
EPS (diluted)——
Balance sheet
Cash & equivalents$428,700$822,799
Current assets$1.24M$1.20M
Total assets$17.13M$119.80M
Current liabilities$1.83M$722,230
Total liabilities$1.83M$722,230
Shareholders' equity-$681,323$1.11M
Shares outstanding4.25M4.25M
Cash flow statement
Operating cash flow-$1.32M-$820,959
Investing cash flow$107.84M-$115.58M
Financing cash flow-$106.13M$117.17M
Share buybacks$106.13M—

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.